(ChemotherapyAdvisor) – VeriStrat may be useful for clinical decision-making in patients with non-small cell lung cancer (NSCLC), according to a study presented by a multinational team of researchers at the third annual European Lung Cancer Conference in Geneva, Switzerland. The study, entitled “Serum Proteomic Classifier for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Erlotinib and Bevacizumab in First Line: Pooled Analysis of Phase 2 Trials SAKK19/05 AND NTR528,” is listed as Abstract# 80O_PR.
VeriStrat is a proteomic-based serum test that reports two labels: VeriStrat Good (VSG) or VeriStrat Poor (VSP); according to published studies, VSG patients perform better than VSP patients upon treatment with EGFR TKIs. The authors aimed to explore VeriStrat’s ability to separate patients with advanced non-squamous NSCLC treated with bevacizumab and erlotinib (BE) into groups based on their progression-free survival (PFS) and overall survival (OS). Data were obtained from 117 patients previously enrolled in 2 European Phase 2 trials of first-line BE (NCT00354549 and NTR528) and analyzed using VeriStrat.
The authors reported that VeriStrat analysis classified 87 (74%) as VSG, 27 (23%) as VSP, and 3 (3%) as indeterminate. “VSG and VSP demonstrated a statistically significant difference in OS (P=0.0027, HR=0.480, 95% confidence interval (CI): 0.294–0.784) but significance for PFS was not reached (P=0.2632, HR=0.768, 95% CI: 0.482–1.223).”
The authors concluded: “These results support the notion that VeriStrat may be useful for clinical decision-making, representing a prognostic and potentially a predictive biomarker for treatment with EGFR TKIs. This predictive value of VeriStrat will be tested in a prospective clinical trial in advanced squamous cell lung carcinoma, sponsored by the European Thoracic Oncology Platform (ETOP).”